elbasvir grazoprevir
Selected indexed studies
- Elbasvir/grazoprevir. (Aust Prescr, 2017) [PMID:28246435]
- Elbasvir and grazoprevir for the treatment of hepatitis C. (Expert Rev Anti Infect Ther, 2021) [PMID:33428488]
- Elbasvir/Grazoprevir: First Global Approval. (Drugs, 2016) [PMID:26943930]
_Worker-drafted node — pending editorial review._
Connections
elbasvir grazoprevir is a side effect of
Sources
- Elbasvir/grazoprevir. (2017) pubmed
- Elbasvir and grazoprevir for the treatment of hepatitis C. (2021) pubmed
- Elbasvir/Grazoprevir: First Global Approval. (2016) pubmed
- Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4. (2017) pubmed
- Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C. (2017) pubmed
- Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. (2017) pubmed
- Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. (2018) pubmed
- Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. (2022) pubmed
- Elbasvir/Grazoprevir. (2016) pubmed
- Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. (2016) pubmed